Genor Biopharma Holdings Beheer

Beheer criteriumcontroles 2/4

De CEO Genor Biopharma Holdings is Feng Guo, benoemd in Apr2020, heeft een ambtstermijn van 4.58 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 24.29M, bestaande uit 18.5% salaris en 81.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.35% van de aandelen van het bedrijf, ter waarde HK$ 12.92M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 2.9 jaar.

Belangrijke informatie

Feng Guo

Algemeen directeur

CN¥24.3m

Totale compensatie

Percentage CEO-salaris	18.5%
Dienstverband CEO	4.6yrs
Eigendom CEO	1.3%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	2.9yrs

Recente managementupdates

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 20

Recent updates

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 20

Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation

May 29

We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

Dec 29

We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Dec 21

Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

Sep 05

We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Dec 03

Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Aug 28

Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?

May 10

Analyse CEO-vergoeding

Hoe is Feng Guo's beloning veranderd ten opzichte van Genor Biopharma Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CN¥526m
Mar 31 2024	n/a	n/a	-CN¥600m
Dec 31 2023	CN¥24m	CN¥5m	-CN¥674m
Sep 30 2023	n/a	n/a	-CN¥637m
Jun 30 2023	n/a	n/a	-CN¥599m
Mar 31 2023	n/a	n/a	-CN¥665m
Dec 31 2022	CN¥32m	CN¥5m	-CN¥730m
Sep 30 2022	n/a	n/a	-CN¥800m
Jun 30 2022	n/a	n/a	-CN¥870m
Mar 31 2022	n/a	n/a	-CN¥868m
Dec 31 2021	CN¥41m	CN¥5m	-CN¥865m

Compensatie versus markt: De totale vergoeding ($USD 3.41M ) Feng } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 234.08K ).

Compensatie versus inkomsten: De vergoeding van Feng is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Feng Guo (54 yo)

4.6yrs

Tenure

CN¥24,285,000

Compensatie

Dr. Feng Guo Ph D., served as Chairman of the Board for Genor BioPharma Co., Ltd. since November 2021 until September 12, 2024.He served as Chairman at Genor Biopharma Holdings Limited since November 02,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Feng Guo	Chief Executive Officer	4.6yrs	CN¥24.29m	1.35% HK$ 12.9m
Chengyi Weng	CFO, Company Secretary & Executive Director	no data	geen gegevens	0.067% HK$ 641.7k
Qibin Liang	Chief Technology Officer	3.1yrs	geen gegevens	geen gegevens
Shuhua Han	Chief Scientist	3.8yrs	geen gegevens	geen gegevens
Xiaojing Zhu	Vice President of Compliance & Administration	no data	geen gegevens	geen gegevens
Tong Li	Chief Medical Officer	4.3yrs	geen gegevens	geen gegevens
Tak Wai Ip	Company Secretary	2.4yrs	geen gegevens	geen gegevens
Jun Lin	Vice President of Quality Analysis	4.8yrs	geen gegevens	geen gegevens
Qingtang Duan	General Manager of Yuxi Genor	5.3yrs	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 6998 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Chengyi Weng	CFO, Company Secretary & Executive Director	less than a year	geen gegevens	0.067% HK$ 641.7k
David J. Kerr	Member of Scientific Advisory Board	2.9yrs	geen gegevens	geen gegevens
Leonard B. Saltz	Member of Scientific Advisory Board	2.9yrs	geen gegevens	geen gegevens
Wen Chen	Independent Non-Executive Director	4.4yrs	CN¥420.00k	geen gegevens
Alex A. Adjei	Member of Scientific Advisory Board	2.9yrs	geen gegevens	geen gegevens
Edwin Fung	Independent Non-Executive Director	4.4yrs	CN¥420.00k	geen gegevens
Dong Lyu	Non Executive Director	3yrs	geen gegevens	geen gegevens
Zhijian Chen	Chairman of Scientific Advisory Board	3.5yrs	geen gegevens	geen gegevens
Yangxin Fu	Member of Scientific Advisory Board	2.9yrs	geen gegevens	geen gegevens
John F. Seymour	Member of Scientific Advisory Board	2.9yrs	geen gegevens	geen gegevens
John R. Zalcberg	Member of Scientific Advisory Board	2.9yrs	geen gegevens	geen gegevens
Yi Liu	Non-Executive Director	2.3yrs	geen gegevens	geen gegevens

2.9yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 6998 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.9 jaar), wat duidt op een nieuw bestuur.

Genor Biopharma Holdings Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Genor Biopharma Holdings Limited Appoints Cui Bai as Independent Non-Executive Director and Member of the Audit Committee of the Board

Genor Biopharma Holdings Limited Announces Resignation of Zhou Honghao as Independent Non-Executive Director and Member of the Audit Committee

Genor Biopharma Holdings Limited Appoints Weng Chengyi as Chief Financial Officer

Genor Biopharma Holdings Limited Announces Directorate Changes

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Genor Biopharma Holdings Limited, Annual General Meeting, Jun 27, 2024

Recent updates

Edding Group Company Limited agreed to acquire Genor Biopharma Holdings Limited (SEHK:6998).

Genor Biopharma Holdings Limited Appoints Cui Bai as Independent Non-Executive Director and Member of the Audit Committee of the Board

Genor Biopharma Holdings Limited Announces Resignation of Zhou Honghao as Independent Non-Executive Director and Member of the Audit Committee

Genor Biopharma Holdings Limited Appoints Weng Chengyi as Chief Financial Officer

Genor Biopharma Holdings Limited Announces Directorate Changes

New minor risk - Shareholder dilution

Genor Biopharma Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation

Genor Biopharma Holdings Limited, Annual General Meeting, Jun 27, 2024

Genor Biopharma Holdings Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Genor Biopharma Holdings Limited Announces China National Medical Products Administration Accepts New Drug Application for GB491 (Lerociclib)

New minor risk - Share price stability

Genor Biopharma Holdings Limited Announces Board Changes

We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

First half 2023 earnings released: CN¥0.54 loss per share (vs CN¥0.81 loss in 1H 2022)

Genor Biopharma Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

New minor risk - Market cap size

Genor Biopharma Holdings Limited Announces Updates on New Product Application Approval of Geptanolimab (GB226) for the Treatment of Relapsed/Refractory Permitting T-Cell Lymphoma

We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Less than half of directors are independent

Genor Biopharma Holdings Limited Announces Launch of Phase I/II Clinical Trial of GB263T in China

Genor Biopharma Holdings Limited Announces Launch of Phase I/Ii Clinical Trial Ofgb261 in China

Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

Genor Biopharma Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

Genor Biopharma Holdings Limited Announces Management Changes with Effect from July 29, 2022

Genor Biopharma Holdings Limited Announces Executive Changes

Genor Biopharma Holdings Limited Obtains Investigational New Drug Approval from the National Medical Products Administration

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Approval for Phase I/II Clinical Trials of GB261

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Approval for Phase I/II Clinical Trials of GB261

Genor Biopharma Holdings Limited Announces First Patient Dosed in the First-In-Humanclinical Trial of GB263T

Less than half of directors are independent

Genor Biopharma Holdings Limited Announces Resignation of Zhou Joe Xin Hua as Executive Director and President

Genor Biopharma Holdings Limited Announces First-In-Human Clinical Trial of GB263T Approval by the Bellberry Human Research Ethics Committee

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Drug Application Approval for GB242 (Infliximab)

We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Genor Biopharma Holdings Limited Announces First Patient Enrolled in the Phase III Clinical Trial of Gb491 in China

Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Consensus forecasts updated

JHBP (CY) Holdings Limited Receives Investigational New Drug Approval for GB492 by National Medical Products Administration

Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?

Non-Executive Director has left the company

Full year 2020 earnings released: CN¥12.36 loss per share (vs CN¥0.94 loss in FY 2019)

JHBP (CY) Holdings Limited Submits a Clinical Trial Application to the Bellberry Human Research Ethics Committee in Australia

JHBP (CY) Holdings Limited to Report Fiscal Year 2020 Results on Mar 23, 2021

JHBP (Cy) Holdings Limited Receives Drug Approvals from the National Medical Products Administration

JHBP (CY) Holdings Limited Appoints Han Shuhua as New Chief Scientist

New 90-day high: HK$23.00

JHBP (CY) Holdings Limited has completed an IPO in the amount of HKD 2.877144 billion.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd